Baxter Announces Long-Term Partnership in Brazil to Expand Access to Recombinant FVIII Hemophilia Treatment

  Baxter Announces Long-Term Partnership in Brazil to Expand Access to
  Recombinant FVIII Hemophilia Treatment

Business Wire

DEERFIELD, Ill. -- November 01, 2012

Baxter International Inc. (NYSE:BAX) today announced an exclusive 20-year
partnership with Hemobrás (Empresa Brasileira de Hemoderivados e
Biotechnologia) to provide hemophilia patients in Brazil greater access to
recombinant factor VIII (rFVIII) therapy for the treatment of hemophilia A.
Hemophilia A is a genetic condition in which the body does not produce enough
clotting protein factor VIII. It is estimated that more than 10,000 people in
Brazil are living with hemophilia A, and today the vast majority are treated
with plasma-derived FVIII therapy.^1

Baxter recently highlighted the importance of developing innovative business
models, including public and private partnerships, aimed at improving the
quality of and access to care in both developed and emerging markets.

''Our unique collaboration with Hemobrás is a demonstration of Baxter’s
leadership in hemophilia, reflects our expertise and commitment to the
community, and positions us as an attractive partner that can make a
significant impact on expanding access to quality care to patients around the
world,'' saidRobert L. Parkinson, Jr., Baxter chairman and chief executive
officer. ''This agreement establishes Baxter as the provider of choice in
Brazil and builds upon Baxter’s long-standing presence in this large and
growing market.''

Through this innovative partnership, Baxter will be the exclusive provider of
Brazil’s recombinant FVIII treatment over the next 10 years while the
companies work together on the technology transfer to support development of
local manufacturing capacity by Hemobrás. Baxter will receive cash payments
for product it supplies to Hemobrás and, following completion of the
technology transfer, royalties on recombinant FVIII produced by Hemobrás. The
company expects peak annual sales to exceed $200 million.

About Hemobrás

Hemobrás is a public company dedicated to creating greater autonomy for the
production of life-saving therapies for people in Brazil with hemophilia,
primary immunodeficiency disease, cirrhosis, severe burns, cancer and AIDS.

About Baxter International Inc.

Baxter has more than 60 years experience in hemophilia and introduced a number
of therapeutic firsts for hemophilia patients. The company has the broadest
portfolio of hemophilia treatments in the industry, supporting individual
therapy choices and providing a range of options at each treatment stage.
Baxter is focused on optimizing hemophilia care and improving the lives of
people living with hemophilia A and B worldwide.

Baxter has been offering plasma-derived FVIII treatments to hemophilia
patients in Brazil since 1979, and recombinant therapy since 1998.

Baxter International Inc., through its subsidiaries, develops, manufactures
and markets products that save and sustain the lives of people with
hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and
other chronic and acute medical conditions. As a global, diversified
healthcare company, Baxter applies a unique combination of expertise in
medical devices, pharmaceuticals and biotechnology to create products that
advance patient care worldwide.

This release includes forward-looking statements concerning a partnership
between Baxter and Hemobrás, including expectations regarding the production
and sale of rFVIII in Brazil and the financial impact of the partnership on
Baxter. The statements are based on assumptions about many important factors,
including the following, which could cause actual results to differ materially
from those in the forward-looking statements: actions of regulatory bodies and
other governmental authorities, including the Brazilian government; changes in
laws and regulations; product quality or patient safety issues; and other
risks identified in Baxter's most recent filing on Form 10-K and other SEC
filings, all of which are available on its website. Baxter does not undertake
to update its forward-looking statements.

^1 Federação Brasileira de Hemofilia. Accessed on: 10 March 2011. Available at


Baxter International Inc.
Media Contacts:
Brian Kyhos, 224-948-4210 (U.S. media)
Tarsis Lopez, 224-921-8353 (Brazil media)
Investor Contacts:
Mary Kay Ladone, 224-948-3371
Clare Trachtman, 224-948-3085
Press spacebar to pause and continue. Press esc to stop.